Andrew Ng

Andrew Ng is an Investment Partner at Panacea Venture, a global healthcare venture capital firm, since 2021. He has over 16 years of experience in the healthcare industry across Asia and the US and has led multiple investments across therapeutics, diagnostics, medical device and CRO/CDMO verticals. He is also the Head of Healthcare at VMS Group, a Hong Kong based asset management firm focusing in growth stage investment.
Prior to that, Andrew was responsible for the China Healthcare Equity Research at Barclays Capital based in Hong Kong. Before that, he was an investment banker covering healthcare clients across the Asia Pacific region at Barclays Capital with a focus in cross-border M&A. Andrew started his career as a management consultant at ZS Associate in the United States advising global pharma on sales & marketing strategy and operations.
Andrew has been on the board of multiple companies that carry out product development, manufacturing and sales in the biotechnology, medical equipment and CXO industries. These companies include New Horizon Health, Chime Biologics, Jade Biomedical, SyMap Medical, Yizun Biomedicine and Profusa.
Andrew received an MBA from INSEAD, a M.Eng. degree and a B.S. degree in Operations Research & Engineering from Cornell University.